H5N1 influenza vaccine, deltaFLU, induced a superior antibody response
by Press Release from Outbreak News Today on (#4HRZ7)
Vivaldi Biosciences, a clinical-stage biotechnology company developing advanced vaccines for seasonal and pandemic influenza, recently announced the publication of Phase 1 clinical trial results for its deltaFLU vaccine for protection against influenza H5N1, a strain with pandemic potential. The data published in the journal Vaccine show that Vivaldi's deltaFLU H5N1 vaccine induced a superior antibody ["]
The post H5N1 influenza vaccine, deltaFLU, induced a superior antibody response appeared first on Outbreak News Today.